Treats illness caused by various strains of influenza A virus. ANDA 76132, held by Impax Labs. Rimantadine Hydrochloride.
As of Nov 16, 2026, ANDA 76132 (Rimantadine Hydrochloride), held by Impax Labs, was first approved by FDA on Aug 30, 2002, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). Prophylaxis In controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza A virus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 30, 2002 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Rimantadine Hydrochloride100MG · tablet;oral | Rimantadine Hydrochloride | Rx |
| Oct 14, 2014 | Supplement 8Manufacturing | Approved | None posted |
| Aug 30, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters